Abstract

Abstract: Aims: Investigation of altered consumption patterns of benzodiazepines and opioids during the early COVID-19 pandemic. Methods: The study sample was extracted from an international web-based survey provided from April to August 2021 in 5 languages; completed by 5049 participants. A retrospective exploration of sociodemographic features, frequencies and dosages of benzodiazepine and opioid use and psychopathology was executed. Quantities of the respective substance use and consumers’ motivations for consumption pre-pandemic versus during the pandemic were compared. Associations between quantities, psychopathology, and positive effects of the substances, negative sequelae and concerns related to COVID-19 were examined. Results: A significant reduction of the consumption quantity was solely found for heroin users. Higher benzodiazepine consumption rates during the pandemic were marginally associated with a greater general psychopathology. Concerns related to the COVID-19 crisis were significantly positively correlated with the symptomatologies of the opioid and benzodiazepine users who presented a higher perception of life restriction. A significant reduction of reported motivations consumption was found for the motive partying. Conclusions: During the early COVID-19 pandemic the quantities and motives of consumption of sedatives and opioids remained mostly stable. The psychopathology of consumers was associated with specific concerns related to the pandemic.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call